OncoSec Medical Inc ONCS

NAS: ONCS | ISIN: US68234L3069   25/08/2023
0,000 USD (0,00%)
(0,00%)   25/08/2023

18 mei 2023 · OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

16 mei 2023 · OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

16 mei 2023 · OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program · Persbericht

27 april 2023 · OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program · Persbericht

11 april 2023 · OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

10 april 2023 · OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

3 april 2023 · OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment · Persbericht

5 december 2022 · OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 · Persbericht

30 november 2022 · OncoSec Announces Pricing of $3.5 Million Public Offering · Persbericht

15 november 2022 · OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma · Persbericht

11 november 2022 · OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment · Persbericht

8 november 2022 · OncoSec Announces Reverse Stock Split · Persbericht

4 oktober 2022 · OncoSec Announces Pipeline Prioritization and Workforce Reduction · Persbericht

24 juni 2022 · Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research · Persbericht

23 mei 2022 · OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research · Persbericht

29 april 2022 · OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer · Persbericht

22 februari 2022 · OncoSec Announces Appointment of George Chi as Chief Financial Officer · Persbericht

17 december 2021 · OncoSec Announces Changes to its Board of Directors · Persbericht

2 november 2021 · OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study · Persbericht

20 oktober 2021 · OncoSec Provides Business Update · Persbericht

Mijn selecties